More importantly, glioma patients with concomitantly high DRD2 and β-catenin have shorter overall survival than patients with concomitantly low expression (Fig. 5K), suggesting that the combined detection of DRD2 and β-catenin could be a key outcome measure in glioma patients with depression. This evidence concerns the gene DRD2 and depressive disorder.